Tag: antibody-based therapies
June 6, 2018
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment... May 9, 2018
argenx reports first quarter 2018 financial results and provides business update
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment... March 22, 2018
argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117
argenx (Nasdaq:ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune... March 31, 2017
